OBIO CAAP Company: Biotagenics Partners with University of Ottawa and CHEO on $9.1 Million Project with Genome Canada to Develop Therapies for Inflammatory Bowel Disease

Toronto – Biotagenics Inc., a microbiome-based platform company developing novel therapeutics and diagnostics is the industrial collaborator on a $9.1 million CAD ($7.4 million USD) project led by academic collaborators at University of Ottawa and Children’s Hospital of Eastern Ontario (CHEO) to study the clinical application of microbiome-based precision medicine in pediatric inflammatory bowel disease (IBD).

There is a clear need for a new approach in the diagnosis and management of IBD. We believe that our research as well as that of our academic collaborators is the next step for the development of a new patient-centric framework based on cutting-edge multi-omic insights on the relationship between the gut microbiome and the patient
— Tom Cirrito, CEO, Biotagenics